Microbix Announces Appointment to Board of DirectorsAppointing Accomplished Business Leader Jennifer Stewart
MISSISSAUGA, Ont., Feb. 22 2022 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces that Ms. Jennifer Stewart, an accomplished leader in Canadian business, government and public affairs, has been nominated to serve on its Board of Directors.
If nominated by a majority of shareholders voting at Microbix’s Annual General Meeting on Wednesday, March 30, 2022, Ms. Stewart will join the Board of Directors and will also be invited to serve on the Human Resources, Compensation and of governance.
Ms. Stewart is Founder, President and CEO of Syntax Strategic, a leading advocacy and communications company for the public and private sectors. She is recognized as an expert in this field, often approached by national media for commentary. In addition, Ms. Stewart has twice been named one of Ottawa’s “Top 25 People in the Capital” by Ottawa Life magazine, one of Ottawa’s “Top 40 Under 40” by the Ottawa Business Journal and the Ottawa Chamber of Commerce, and was a finalist for Ottawa’s “Established Woman Entrepreneur of the Year”.
Ms. Stewart has a journalism and communications degree from Carleton University (Ottawa, ON) and has been actively involved in many business and community affairs roles. Her participations have included the President and CEO of the Canadian Independent Petroleum Marketers Association (CIPMA), Chair of the Board of Directors of the Canadian Transportation Alliance, co-host and co-founder of The Honest Talk podcast, President of the Village of Carp Business Improvement Association. , Board Member of the Youth Services Bureau of Ottawa Foundation, Board Member of the Women in Technology Scholarship at Willis College and Board Member of the Cancer Foundation of the Ottawa region.
Martin Marino, Independent Chairman of the Board of Microbix, said, “I am delighted to welcome Jennifer on behalf of the directors, management, staff and shareholders of Microbix. Jennifer will add her skills, connectivity, broad perspectives and expertise to our board-level leadership. His appointment follows a process by which our Board evaluated several qualified candidates.
Jennifer Stewart also remarked on her appointment, “I have seen how Microbix improves the public health of Ontarians and Canadians. If appointed, I look forward to helping Microbix achieve even greater success with its medical devices that support the global diagnostics industry. As a board member, I will be committed to accelerating its pace of value creation in a way that also serves the public good.
Upon her appointment, Ms. Stewart will be granted options to purchase common shares. The options will have an exercise price set by the closing price of Microbix shares on the TSX the day before they are granted, a term of five years and will vest after three years.
About Microbix Biosystems
Microbix develops proprietary biological and technological solutions for human health and well-being, with approximately 100 skilled employees and sales of nearly C$2.0 million per month. It manufactures a wide range of critical biological materials for the global diagnostics industry, including antigens for immunoassays and its Quality Laboratory Assessment Products (QAPs™) that support clinical laboratory proficiency testing, enable the development and validation of tests, or help ensure the quality of clinical diagnosis. workflow. Microbix antigens enable antibody testing from more than 100 international diagnostic companies, while its QAPs are sold to clinical laboratory accreditation bodies, diagnostic companies and clinical laboratories. Microbix QAPs are now available in over 30 countries, distributed by 1WA (Oneworld Accuracy Inc.), Alpha-Tec Systems, Inc., Diagnostic International Distribution SpA, Labquality Oy, The Medical Supply Company of Ireland, R-Biopharm AG, SDT Molecular Pte Ltd, Seegene Canada Inc. and Thomas Scientific LLC. Microbix is ISO 9001 and 13485 accredited, registered with the US FDA, registered with the Australian TGA, approved by Health Canada and provides CE marked products.
Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, including Viral Transport Medium (DxTM™) to stabilize patient samples for molecular diagnostic laboratory testing and Kinlytic® urokinase, a biological thrombolytic drug used to treat blood clots. Microbix is listed on the TSX and OTCQB and is headquartered in Mississauga, Ontario, Canada.
This press release contains “forward-looking information”, as that term is defined in applicable securities laws. Forward-looking information includes, but is not limited to, all discussions regarding Ms. Stewart or her qualifications, opinions about her or others, the role or actions of the board of directors, Microbix’s business activities and results, objectives or prospects, risks associated with financial results and stability, development projects such as those referenced in its corporate presentation, compliance and regulatory approvals, sales to domestic or foreign jurisdictions, the engineering and construction, production (including cost control, quality, quantity and delivery times), foreign currencies and exchange rates, maintaining adequate working capital and raising additional capital on terms acceptable or not at all, and other similar statements regarding anticipated future events, conditions or results that are not historical facts. These statements reflect management’s current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking information is inherently uncertain and that actual performance may be affected by a number of important factors, many of which are beyond the Company’s control. Accordingly, actual future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied by the forward-looking information. All statements are made as of the date of this press release and represent the judgment of the Company as of the date of this new press release, and the Company undertakes no obligation to update or change any forward-looking information.
Please visit www.microbix.com or www.sedar.com for the latest Microbix news and filings.
For more information, please contact Microbix at:
|Cameron Groome, CEO
Adelaide Capital Markets
Capital of the Torrey Hills
Copyright © 2022 Microbix Biosystems Inc.
Microbix®DxTM™, Kinlytic®and QAPs™ are registered trademarks of Microbix Biosystems Inc.